$1.75
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 154 full-time employees. The company went IPO on 2020-09-18. The firm focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.
Country

BE

CEO

Mr. Olivier Taelman

IPO date

2020

Employees

154

ISIN

BE0974358906

Key stats

Open

$1.70

Volume

273.48K

Market cap

$165.74M

Prev. close

$1.67

Impl / hst vl

-

Open interest

$0.00

$1.70

Day’s Range

$1.75

$1.26

52W Range

$5.39

Valuation

27
Valuation score
Overvalued
P/E
-
P/S
10.86
P/B
4.04
Current ratio
0.99
Debt / Equity
0.65
ROE
-159.82%
Gross margin
57.09%
Income growth
-32.19%
FCF growth
68.00

Analysts estimates

Consensus rating
Buy

The average rating from top 7 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$6.33
The top 6 analysts forecasts that 12-month price may increase by 261.94%, with a low of $3.92 and a high of $9.66
$3.92
Low
$6.33
Avg
$9.66
High
Current price

Earnings

Q1 ‘26 revenue
$7.28M
Q1 ‘26 net income
-$18.21M
Revenue
Net income
Previous EPS
-$0.42
Estimate EPS
-$0.45
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply